UBS Group
NVAX icon

UBS Group’s Novavax NVAX Stock Holding History

UBS Group’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-27,900
Closed -$242K – 10972
2025
Q3 		$242K Hold
27,900
– – ﹤0.01% 6564
2025
Q2 		$176K Buy
+27,900
New +$185K ﹤0.01% 6808
2024
Q3 		– Sell
-36,700
Closed -$465K – 9895
2024
Q2 		$465K Buy
+36,700
New +$369K ﹤0.01% 5059
2023
Q1 		– Sell
-600
Closed -$6.17K – 10129
2022
Q4 		$6.17K Buy
+600
New +$10.6K ﹤0.01% 9072
2022
Q3 		– Sell
-29,000
Closed -$1.49M – 10736
2022
Q2 		$1.49M Sell
29,000
-10,000
-26% -$518K ﹤0.01% 3381
2022
Q1 		$2.87M Sell
39,000
-38,500
-50% -$3.43M ﹤0.01% 3095
2021
Q4 		$11.1M Buy
77,500
+47,500
+158% +$8.16M ﹤0.01% 2052
2021
Q3 		$6.22M Hold
30,000
– – ﹤0.01% 2444
2021
Q2 		$6.37M Buy
+30,000
New +$5.5M ﹤0.01% 2439
2016
Q1 		– Sell
-15
Closed -$3K – 8002
2015
Q4 		$3K Hold
15
– – ﹤0.01% 7892
2015
Q3 		$2K Hold
15
– – ﹤0.01% 8091
2015
Q2 		$3K Sell
15
-25
-63% -$4.39K ﹤0.01% 8076
2015
Q1 		$7K Sell
40
-440
-92% -$71.4K ﹤0.01% 7910
2014
Q4 		$57K Buy
+480
New +$50.2K ﹤0.01% 6326

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group's NVAX Position: Q1 2026 in Review

UBS Group reduced its Novavax (NVAX) stake by 8.5% in Q1 2026, selling an estimated $3.78M and leaving 4,477,701 shares worth $36.4M. The position accounts for 0.01% of the portfolio, ranked #1961.

UBS Group first reported a position in NVAX in Q4 2014 and has held it in 46 quarters since. The position peaked at $39M in Q4 2024. 258 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

  • UBS Group held 4,477,701 shares of Novavax worth $36.4M as of Q1 2026.
  • UBS Group sold 416,583 Novavax shares in Q1 2026, an estimated $3.78M.
  • Novavax made up 0.01% of UBS Group's portfolio in Q1 2026, its #1961 holding.
  • UBS Group first reported a position in Novavax in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Novavax position peaked at $39M in Q4 2024.
  • 258 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.